BRIEF-Merck & Co and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

Thu Jul 28, 2016 2:55am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 28 (Reuters) - Merck & Co Inc :

* Merck and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China

* Merck and AmoyDx plan to implement ADX-SuperARMS liquid biopsy RAS test in Chinese medical centers in 2017

* Plan to expand into other markets such as Argentina, India, Mexico, Taiwan, Hong Kong, Brazil, and Russia by 2019

* Test will be developed using AmoyDx real-time polymerase chain reaction technology,ADX-SuperARMS,will be made available in China in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom)